Over the past twenty-five years, Dr. Howe founded five successful start-up ventures in the medical technology and information systems business sector. In his past role as Chief Executive Officer of his companies, he worked with venture capital and investment banking firms obtaining their participation while moving these companies into commercialization. As the former chairman and CFO of Reliant Technologies he co-lead the efforts to secure funding and successfully re-lauch the company. Reliant Technologies is a medical laser company that developed and launched a revolutionary, FDA-approved medical laser for skin surgery known as Fraxel. He is the former CEO and current Board Member of Cardiovascular Systems, a company with an FDA-approved technology that removes atherosclerotic blockages in peripheral arteries. With FDA approval, Cardiovascular Systems has now moved into an aggressive commercialization phase.

As CEO and Founder of National Information Systems, Inc. (one of his start-up ventures), a leading customer and marketing research company, his company was responsible for conducting extensive marketing and branding campaigns, marketing assessments, and trend research in both business-to-business and business-to-consumer environments for leading Fortune 500 corporations. Metrix Communications, (another of his ventures), was one of the most successful IBM Premium Partners that focused on the development of custom applications for Internet, Manufacturing, and Supply Chain Management. The company developed sophisticated, award winning integrated systems primarily for Fortune 100 corporations.

Dr. Howe is an investor in several ventures and serves on the Board of Directors for several companies including: BioPharma Scientific, a pioneer in the emerging field of combining nutraceuticals with proprietary pharmaceutical delivery; Cardiovascular Systems; Americas Back Medical Clinic which has technology that treats back pain; and Whitsett Hill Entertainment, a company that develops, produces major motion pictures.

He has authored and co-authored three books and several articles, which served as the foundation for promoting his businesses. His books, Quality on Trial, and Customer Relationship Management, were best sellers among business books and have been translated and published in several languages.

Dr. Howe is actively involved in a not for profit organization Boundary Waters Experience, an organization dedicated to providing young people with adventurous experiences in the wilderness. He resides in San Diego, California with his wife, Irene. He is the father of two sons, Ryan and Derek, and has two granddaughters.

back to top


Dr. Maynard Howe brings a richly diverse background to Stemedica. Along with his brother, Roger, he has launched five successful ventures in the medical device, software, testing and measurement, quality and consulting fields. Most recently, as Co-Chairman and CEO of Reliant Technologies, he led a team of scientists, engineers and physicians in developing, testing and launching the revolutionary medical laser for skin surgery known as Fraxel.

The Fraxel is an award winning medical laser technology that has resulted in defining a new category of science called fractional photothermolysis. This new science involves the role of lasers and the patients own stem cells in wound healing and dermatological and plastic surgery. The Fraxel laser, in conjunction with autologous and allogeneic stem cells is currently being used in new clinical study to treat scars, burn scars and diabetic ulcers. Reliant Technology has achieved a strong intellectual property position with over 20 patents issued and 40 pending applications. In addition, Reliant has secured 13 FDA clearances, and is well on its way to becoming the market leader with distribution in over 15 countries.

During his leadership tenure at Reliant, he lead the team responsible for securing funding from individual and institutional investors including: Three Arch Partners, Pinnacle Venture Partners, Meritech Capital Partners, Delphi Ventures and Comerica Bank. Reliant has recently filed an S1 with underwriter representation from investment bankers Piper Jaffrey, Banc of America Securities, Jeffries and Company and RBC Capital Markets.

Prior to Reliant helped more than fifty Fortune 500 companies coordinate their company-wide quality and customer relationship initiatives. As a senior executive and co-founder of a leading customer and market research company, he was responsible for conducting extensive marketing and branding campaigns, market assessments and trend research in both business-to-business and business-to-consumer environments. Maynard is also co-founder and Chairman of BioPharma Scientific, a leading edge company specializing in the integration of pharmaceutical nanotechnology into the field of nutraceuticals. He has experience in setting up distribution and managing sales channels throughout North America, Europe and parts of Asia.

Maynard holds a Bachelor of Science Degree, Master of Science Degree and a Doctorate in Psychology. His ability to recruit world leaders and industry experts and create a culture of innovation and teamwork has contributed to the successes achieved in the businesses he has co-founded and those in which he has provided services as a board member and consultant.

Dr. Howe is the author and co-author of numerous articles and top selling business books. He is a nationally and internationally recognized speaker and lecturer. His benchmark book on quality, Quality on Trial, Bringing Customer Relationships into Focus, is in its second edition and has been published in several languages. Other books include a five part implementation manual series, Business to Business Marketing Management System, published by McGraw-Hill.

He is actively involved as a Board Member and Chairman of the Advanced Development Committee for Alliant International University. Dr. Howe continues to Chair Doctoral Dissertations in the Behavioral Science Field.

back to top


Dr. Tankovich is a recognized innovator, researcher and educator for laser applications in medicine, cancer vaccines, stem cell therapies and other medical related disciplines. He is a proven researcher and has inventions that have set the basis for entire new industries. Founder and Director of several corporations, Dr. Tankovich is respected worldwide and published and honored for his innovative work in laser and new drug usage including medical and aesthetic applications. He has more than 110 US and other foreign patents issued and pending.

Dr. Tankovich has been an educator at international universities, published more than 60 articles and has been a presenter or speaker at over 200 conferences or seminars. He has conducted extensive research and development of laser applications for medical usage as well as for cancer research. Among his numerous awards and honors is the Gold Kurchatov Medal for the Atomic Science Application in Medicine and Biology awarded by the Atomic Energy Agency in 1998. Dr. Tankovich's inventions include devices for laser hair removal and laser skin peeling, non-ablative wrinkle removal, and laser lancet (all three licensed and FDA approved). He was the first in the world to propose, invent, develop, patent, build and use a 1.54 micron Er:Glass laser for medical applications. He is a scientific advisor to Reliant Technology and is the pioneer of the science of Laser Sparing Technology, the supporting intellectual property of the Fraxel Laser and the genesis of what is now known as fractional photolysis.

Dr. Tankovich has conducted extensive research and development of laser applications for medical usage, stem cell therapies, and cancer research. As a result of his advanced technology laser applications in plastic and cosmetic surgery and dermatology, ThermoLase Corporation was founded and still uses his intellectual property and patents on laser hair removal and skin resurfacing. Dr. Tankovich also has worked on laser diagnosis and surgery of malignant and background diseases of uterine cervix and the intraoperation laser diagnosis of early forms of breast cancer. He holds an MD degree from Semashco Medical University (Moscow), a Master of Science degree in Plasma Physics from Moscow University, and a PhD in BioPhysics from Lomonosov Moscow University.
Full Biography >>>

back to top


Dr. Kharazi is a physician by training. He finished Medical School in 1978 in Kiev, Ukraine, where he earned his MD degree in internal medicine and pathology. From 1978 to 1981 he was a postdoctoral fellow at the Kiev Institute of Gerontology. Dr. Kharazi received extensive training in cell biology and immunology, including tissue culture and subsequently earned his PhD in immunology. He studied age-related pathological changes of the immune system in mice and humans and his research interests included the possibility of restoring immunity in aged mice using stem cells from young adult mice. Dr. Kharazi was one of the first to discover the inhibitory effects of old thymus in mice and later published on this subject.

In 1989 Alex was invited to work as a research fellow in the department of Pathology at the Tokyo Metropolitan Institute of Gerontology in Japan. There he studied early progenitors for adult thymic epithelial cells and successfully established adult thymic epithelial cell lines. He received extensive training in immuno-cytology and flow cytometry.

In 1991 Dr. Kharazi was invited to UCLA to serve as Chief Pathologist of an EPA-controlled study on the effects of magnetic fields on the incidence of lymphoma in mice. While at UCLA he received extensive training in U.S. Good Laboratory Practices and regulatory affairs. The results of the study were reported to the United States Congress. From 1998 through 2006 Dr. Kharazi served as Chief Scientist of the Immunotherapy laboratory at St. Vincent Medical Center in Los Angeles, California. There, his research interests focused on cancer treatment using tumor vaccines, which were designed and manufactured to activate a patient’s own immune system. He successfully designed, prepared, and patented a breast cancer vaccine using genetic engineering. He also conducted scientific work on the role that dendritic cells play in the generation of anti-tumor immune response. Dr. Kharazi has hands-on experience in conducting FDA approved clinical trials.

Dr. Kharazi has published over 30 research articles in scientific journals and has contributed to several chapters in scholarly books. He has presented his data at numerous national and international scientific meetings. He is an active member of many distinguished societies such as The American Association for Cancer Research. In addition, he served as a consultant to several research companies and he has also been a faculty member at the University of Southern California in Los Angeles.
Full Biography >>>

back to top


Dr. Baranov is an internationally recognized leading researcher, innovator and educator for applications of physical chemistry, biophysical methods and imaging technology in cancer research and biotech related disciplines. He has published more than 60 articles (including publications in such highly-ranked scientific journals as Cell, Cancer Cell, and Proceedings of National Academy of Sciences of the USA). He has presented the results of his research at over 30 conferences and seminars worldwide.

Dr. Baranov has been an educator at several international universities and an inventor of three U.S. patents. He was also a consultant for several U.S. companies specializing in nutrition, cosmetics and cancer research. Dr. Baranov's research has been significant in the anthracycline drugs' cell membrane transport kinetics and their interaction with DNA; the development of vital fluorescent dye and laser based technology for the early cancer diagnosis for clinical usage; the implementation of a double derivative method for data image analysis of collagen structure in normal and pathological tissues (breast cancer and diabetes); the application of fluorescent, polarized, and nanosecond time-resolved spectroscopy for studies of drug interactions and their molecular complexes with their targets.

back to top


Derek is currently the VP of Operations of Stemedica. He has particular expertise in working with start up organizations. During his tenure he served as Chief Operating Officer and Chief Financial Officer of four different start-up companies and built the financial, personnel, and administrative infrastructure necessary for growth, raising capital and expanding the company's resources with a variety of financing mechanisms. Derek has completed several mergers and acquisitions. He has worked as COO/CFO in the medical, technology, nutritional, and entertainment industries.

Derek serves as the Founder and Executive Chairman of CornerStone Ministries as well as a Board member for BioPharma Scientific. He has played an integral role in the development of numerous growth oriented companies and has provided strategic and tactical consulting to many established organizations. Derek received his B.S. in Business Administration with an emphasis in Accounting and Finance from Northwestern College. He graduated Summa Cum Laude.

back to top


Harris Brotman, PhD, JD is Vice President of Intellectual Property. Dr. Brotman develops intellectual property strategies to implement and execute the Company's business plans. In industry and academia, he has broad strategic experience in biotech, therapeutics and diagnostic patent preparation, prosecution, and licensing for monetizing intellectual property value.

He earned a PhD in genetics from The University of California Davis, and joined the faculty of Cornell University as assistant professor of genetics. Dr. Brotman, as a free-lance journalist, reported for the New York Times Magazine, the Los Angeles Times, and Chicago Tribune on new technologies in human reproduction. He received a law degree from Southwestern University in Los Angeles in 1989, and practiced patent law at partner level in major San Diego law firms prior to joining Stemedica in 2006.

 

back to top


Dave McGuigan brings thirty years of marketing, branding and marketplace development experience to Stemedica. Dave’s marketing leadership has helped launch innovative marketing and public relations initiatives for such organizations as the NHL Detroit Red Wings, (IMG) International Management Group, Marketing Resources, USAA Insurance, Project Concern International and Children’s Hospital of San Diego.

Dave has extensive experience in the delivery of these high profile marketing and public relations campaigns through multiple distribution channels including motion picture, television, internet and print media. Dave sits on the Board of several for-profit and non-profit organizations, and brings a wealth of organizational and strategic expertise to Stemedica.

 

back to top


Dr. Howe is the owner and Medical Director of the San Diego Clinic of Preventive Medicine, which is a private medical clinic specializing in the most current treatments in alternative, as well as mainstream medicine. As both a medical physician, and a chiropractor, Dr. Howe has had extensive training in clinical nutrition throughout his thirty years in the medical field, and incorporates this natural approach to health

Dr. Howe is a member of the American College for Advancement in Medicine, and a member of the American College of Osteopathic Pain Managements and Sclerotherapy






back to top


Mr. Vitums was the Manager of Financial Reporting at Nanogen, Inc., a publicly-traded NASDAQ biotech company, where he was responsible for managing internal and external financial reporting. During his time at Nanogen, he was responsible for implementing a worldwide financial reporting and budgeting system, helped the Company raise approximately $60 million in equity and royalty financing and integrated the financial reporting and budgeting of the four entities Nanogen acquired during this period. From May 2000 to December 2005, Mr. Vitums worked at Cytori Therapeutics, a publicly traded NASDAQ regenerative-cell (stem cell) company, holding various positions, most recently as the Controller. He was also responsible for managing the internal and external financial reporting at the company and was a leader in the team that took the company public on the Frankfurt Stock Exchange in Germany in August of 2000. Prior to Cytori Therapeutics, Mr. Vitums worked at various public accounting firms including PriceWaterhouseCoopers. Mr. Vitums graduated Cum Laude, with a Bachelors degree from Wayne State University in Detroit, Michigan and is a Certified Public Accountant.

back to top


Alexei Lukashev brings 20 years experience in advanced research and development in solid state and eximer lasers, nonlinear optics and interaction of laser radiation with matter. Dr. Lukashev currently works with a laser for hydrogen bond modification which was invented while he was working at Moscow’s General Physics Institute with Nobel Prize Winner and Academician A. Prokhorov. Dr. Lukashev has a long track record of new product development for the medical and semiconductor industries including lasers for hair removal, vascular treatment and skin resurfacing. He has also participated in the development of optical methods of non-invasive cancer diagnostics and was the managing director of development and manufacturing of DermaChiller 4, an FDA-approved hand-held device for cooling the skin during laser and medical procedures.

Dr. Lukashev currently holds 7 US patents and has been published in 36 peer review journals and conference proceedings.

back to top